Difference between revisions of "Bone sarcoma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "'''Use of this site is subject to you reading and agreeing with the terms set forth" to "{|style="width: 100%; border-left:solid 20px #dc143c;border-right:solid 20px #dc143c;border-top:solid 20px #dc143c;border-bottom:solid 20px #dc143c;" align="center" | <span style="font-family:Arial; font-size:200%"> Hello!<br> We're happy that you've chosen to use HemOnc.org, and hope that you will return often. From now until January 31, we are conducting a survey to learn more about our users and how we can make the site better and more useful.<br> Please help us by filling it out!<br> '''Link:''' http://j.mp/2BlBaoQ </span> |}<br>'''Use of this site is subject to you reading and agreeing with the terms set forth") |
Warner-admin (talk | contribs) m (Text replacement - "http://www.esmo.org/" to "https://www.esmo.org/") |
||
(44 intermediate revisions by 4 users not shown) | |||
Line 1: | Line 1: | ||
− | + | <span id="BackToTop"></span> | |
− | + | <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px"> | |
− | + | [[#top|Back to Top]] | |
− | + | </div> | |
− | + | {{#lst:Editorial board transclusions|sarcoma}} | |
− | |||
− | </ | ||
− | |} | ||
− | |||
− | |||
− | |||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
− | |<div style="background-color: # | + | |<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div> |
− | <div style="background-color: # | + | <div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div> |
|} | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
− | <big>Note: this page is | + | <big>Note: this page is for subtype-nonspecific bone sarcoma regimens, and some subtypes with very few subtype-specific regimens. Please see the [[:Category:Bone sarcomas|category page]] for links to other sarcoma types or use one of these links: |
+ | *[[Ewing sarcoma]] | ||
+ | *[[Giant-cell tumor of bone]] | ||
+ | *[[Osteosarcoma]] | ||
+ | </big> | ||
=Guidelines= | =Guidelines= | ||
− | ==[ | + | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.''' |
− | *[ | + | ==[https://www.esmo.org/ ESMO]/EURACAN/GENTURIS/PaedCan== |
− | ==[https://www.nccn.org/ NCCN] | + | *'''2021:''' Strauss et al. [https://doi.org/10.1016/j.annonc.2021.08.1995 Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/34500044/ PubMed] |
− | *[https:// | + | **'''2018:''' Casali et al. [https://doi.org/10.1093/annonc/mdy310 Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/30285218/ PubMed] |
+ | **'''2014:''' [https://doi.org/10.1093/annonc/mdu256 Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/25210081/ PubMed] | ||
+ | **'''2012:''' [https://doi.org/10.1093/annonc/mds254 Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/22997441/ PubMed] | ||
+ | **'''2010:''' Hogendoorn et al. [https://doi.org/10.1093/annonc/mdq223 Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/20555083/ PubMed] | ||
+ | |||
+ | ==NCCN== | ||
+ | *[https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1418 NCCN Guidelines - Bone Cancer] | ||
+ | *'''2013:''' Biermann et al. [https://doi.org/10.6004/Jnccn.2013.0088 Bone cancer.] [https://pubmed.ncbi.nlm.nih.gov/23744868/ PubMed] | ||
+ | *'''2010:''' Biermann et al. [https://doi.org/10.6004/Jnccn.2010.0051 Bone cancer.] [https://pubmed.ncbi.nlm.nih.gov/20581300/ PubMed] | ||
+ | *'''2007:''' Biermann et al. [https://doi.org/10.6004/Jnccn.2007.0037 Bone cancer.] [https://pubmed.ncbi.nlm.nih.gov/17442233/ PubMed] | ||
+ | *'''2005:''' Biermann et al. Bone cancer clinical practice guidelines. [https://pubmed.ncbi.nlm.nih.gov/19817025/ PubMed] | ||
=Chondrosarcoma, all lines of therapy= | =Chondrosarcoma, all lines of therapy= | ||
Line 28: | Line 36: | ||
*Dedifferentiated chondrosarcoma has been treated with [[Osteosarcoma|osteosarcoma regimens]] | *Dedifferentiated chondrosarcoma has been treated with [[Osteosarcoma|osteosarcoma regimens]] | ||
− | = | + | =Undifferentiated pleomorphic sarcoma (UPS) of bone, all lines of therapy= |
− | + | *Undifferentiated pleomorphic sarcoma (UPS) of bone has been treated with [[Osteosarcoma|osteosarcoma regimens]] | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | * | ||
− | |||
− | |||
− | |||
[[Category:Bone sarcoma regimens]] | [[Category:Bone sarcoma regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
− | [[Category: | + | [[Category:Bone sarcomas]] |
Latest revision as of 17:51, 23 June 2024
Section editor | |
---|---|
Elizabeth J. Davis, MD Vanderbilt University Nashville, TN, USA |
0 regimens on this page
0 variants on this page
|
Note: this page is for subtype-nonspecific bone sarcoma regimens, and some subtypes with very few subtype-specific regimens. Please see the category page for links to other sarcoma types or use one of these links:
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
ESMO/EURACAN/GENTURIS/PaedCan
- 2021: Strauss et al. Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up PubMed
- 2018: Casali et al. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
- 2014: Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
- 2012: Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
- 2010: Hogendoorn et al. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
NCCN
- NCCN Guidelines - Bone Cancer
- 2013: Biermann et al. Bone cancer. PubMed
- 2010: Biermann et al. Bone cancer. PubMed
- 2007: Biermann et al. Bone cancer. PubMed
- 2005: Biermann et al. Bone cancer clinical practice guidelines. PubMed
Chondrosarcoma, all lines of therapy
- No standard chemotherapy for grades 1 to 3 conventional chondrosarcoma
- Mesenchymal chondrosarcoma has been treated with Ewing's sarcoma regimens
- Dedifferentiated chondrosarcoma has been treated with osteosarcoma regimens
Undifferentiated pleomorphic sarcoma (UPS) of bone, all lines of therapy
- Undifferentiated pleomorphic sarcoma (UPS) of bone has been treated with osteosarcoma regimens